Please Note: THIS FORUM IS PATIENT MODERATED AND IS NOT CONNECTED TO ANY CLINIC OR DOCTOR. IF YOU WISH TO CONTACT A CERTAIN DOCTOR OR CLINIC, PLEASE LOOK IN THE ASK THE DOCTOR SECTION FOR DOCTOR OR CLINIC PHONE NUMBERS AND EMAIL ADDRESSES.

                        Home || Contact Us || Help Registering and Participating || Disclaimer


 SeaChange now offers CBD Oil

 

Barbara and Jeannine's Book

Bea Luis Memorial

 


Results 1 to 4 of 4

Thread: If Biotech Cannot Make Enough Money from Curing Disease Then Move on to Antiaging

  1. #1
    Join Date
    May 2007
    Posts
    12,949
    Blog Entries
    5

    Default If Biotech Cannot Make Enough Money from Curing Disease Then Move on to Antiaging

    Brian Wang | December 1, 2018

    https://www.google.com/amp/s/www.nex...aging.html/amp

    Goldman Sachs analysts asked “Is curing patients a sustainable business model?” analysts ask in an April 10 report entitled “The Genome Revolution.” Goldman was addressing the question of gene therapies that provide complete cures with one treatment.

    “The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” analyst Salveen Richter.

    Gilead Sciences’ treatments can cure more than 90 percent of hepatitis C patients. Gilead hepatitis C treatments peaked at $12.5 billion in 2015 but are now less than $4 billion in 2018.

    Curing infectious diseases (like Hep C) also decreases the number of carriers able to transmit the virus to new patients so complete success means the elimination of the disease. However, cancer has a more constant rate of new patients with the disease that are not based upon infection in almost all cases.

    Company Strategy Suggestions from the Goldman Analysts

    1. Target large markets: Hemophilia is a $9-10 billion worldwide market (hemophilia A, B) is growing at ~6-7% annually.

    2. Address disorders with high incidence: Spinal muscular atrophy (SMA) affects the cells (neurons) in the spinal cord, impacting the ability to walk, eat, or breathe.

    3. Constant innovation and portfolio expansion: There are hundreds of inherited retinal diseases (genetics forms of blindness). The pace of innovation will also play a role as future programs can offset the declining revenue trajectory of prior assets.

    Nextbigfuture Opinion
    Nextbigfuture notes that some biotech companies have a powerful platform for generating many cures. Companies working on RNA interference have a model of rapidly being able to adjust their curing system for the next in a series of diseases. This is similar to the constant innovation but is more systematic.

    This problem would not exist for biotech companies focused upon extreme longevity. There would be the need to constantly repeat antiaging treatments as new aging damage is created.

    Powerful medicine should be in the age of disease cures instead of the age of slight mitigation or symptom reduction. However, beyond the age of curing heart disease, cancer and other diseases is comprehensive repair of aging damage.
    First treatment in 2007. Pioneering ever since.

    Barbara

  2. #2
    Join Date
    Jan 2011
    Location
    Miami, FL
    Posts
    241
    Blog Entries
    1

    Default

    Hi Barb,

    Good to see you're still battling for all of our rights. Thank you my friend!!!

    In retrospect after so many years, the main forces being confronted the statist politicians, greedy researchers, and pharmaceutical companies; all banking on the terminally ill and suffering. We've made some pretty good strides in winning against FDA and state laws in these past "two years." However, something that is very tough to beat is greed. Like I've said before, big pharma will always be in the business of making money and not finding cures. A cure will be the end of their growing market, sad but true.

  3. #3
    Join Date
    May 2007
    Posts
    12,949
    Blog Entries
    5

    Default

    I agree 100% and unfortunately Big Pharma has its tentacles in politics, the media, academia, FDA, NIH, etc.
    First treatment in 2007. Pioneering ever since.

    Barbara

  4. #4
    Join Date
    May 2007
    Posts
    12,949
    Blog Entries
    5

    Default

    First treatment in 2007. Pioneering ever since.

    Barbara

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

Copyright 2007 - 2011 Stem Cell Pioneers